- $1.28bn
- $1.72bn
- $348.97m
MannKind Corp expected to post earnings of 1 cent a share - Earnings Preview
Brief: Mannkind Corp Says Inhaled Insulin Is As Effective As Usual Care For Adults Living With T1D Meeting Primary Endpoint
Brief: Pulmatrix Announces Cross License Agreement And Transfer Of Laboratory To Mannkind Corporation
MannKind Corp expected to post earnings of 3 cents a share - Earnings Preview
Brief: Mannkind Receives U.S. FDA Fast Track Designation For Clofazimine Inhalation Suspension For The Treatment Of Nontuberculous Mycobacterial Lung Disease
Brief: Mannkind To Proceed With Phase 1 Nintedanib Dpi Study For Pulmonary Fibrotic Diseases
Brief: MannKind Announces IND Clearance From U.S. FDA To Start Phase 3 Study Of Clofazimine Inhalation Suspension For Nontuberculous Mycobacterial Lung Disease
Brief: Mannkind Corp Repaid Credit And Security Agreement With Midcap Financial Trust In Full For About $31.6 Mln
Brief: MannKind Announces CFO Transition
Brief: MannKind Corp reports Initial Meal Challenge Results Comparing Afrezza Head-To-Head With Multiple Daily Injections And Insulin Pumps
MannKind Corp reports results for the quarter ended in December - Earnings Summary
MannKind Corp expected to post breakeven results a share - Earnings Preview
Brief: MannKind, Sagard Healthcare Enter Royalty Purchase Agreement For Up To $200 Mln
Brief: MannKind Corp- Entered Into Seventh Amendment To Supply Agreement With Amphastar Pharmaceuticals
Brief: MannKind Q3 Operating Income USD 5.097 Million
Brief: MannKind Announces Completion Of Enrollment In U.S. Phase 4 INHALE-3 Trial In Patients Living With Type 1 Diabetes
MannKind Corp expected to post a loss of 2 cents a share - Earnings Preview
Brief: Mannkind Expands Patent Portfolio With New Clofazimine Formulation Patent
U.S. RESEARCH ROUNDUP-Corning, Juniper Networks, Mirati Therapeutics